Previous 10 | Next 10 |
home / stock / cara / cara articles
Shares of Paymentus Holdings, Inc. (NYSE: PAY) rose sharply in today’s pre-market trading after the company reported better-than-expected fo...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Cara Therapeutics Inc (NASDAQ: CARA) announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Transaction supports progression of late-stage oral difelikefalin clinical programs Non-dilutive capital expected to extend cash runway into 2025 ...
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading ...
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 111% to $0.4000. Avinger, Inc. (NASDAQ: AVGR) surged 63.2% to $6.75 amid the company announcing...
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results. AERWINS Technolo...
STAMFORD, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...